In breast cancer, the selective estrogen receptor modifier, tamoxifen, inhibits the expression of ETV4 and ETV5 messenger ribonucleic acid (mRNA), which could reduce the risk of breast cancer [23]. Here, ESR1 is linked to breast carcinoma.